MdxHealth (TM) : MDxHealth Signs Agreement with Stratose® to Expand Insurance
Coverage for ConfirmMDxTM for Prostate Cancer Test
IRVINE, CA, and HERSTAL, BELGIUM -- September 3, 2013 - MDxHealth SA (NYSE
Euronext: MDXH), a leading molecular diagnostic company that develops and
commercializes epigenetic tests to support the diagnosis and treatment of
cancer patients, today announced that it has entered into an agreement with
Stratose, one of the largest healthcare PPO network providers in the U.S. The
agreement provides Stratose's 12.4 million member network with access to
ConfirmMDx for Prostate Cancer testing.
ConfirmMDx for Prostate Cancer provides urologists and their patients with a
non-invasive approach to address false-negative biopsy concerns. The test
provides urologists with actionable information on the decision for repeat
biopsy, aiding in the stratification of patients at sufficiently low risk who
may avoid repeat biopsy and return to screening, from those who may be at
increased risk for harboring undetected cancer, meriting repeat biopsy and
"MDxHealth continues to work with payers and specialty networks to expand
patient and customer access to the ConfirmMDx for Prostate Cancer test.
Stratose's network supplements more than 90 different third-party insurance
payers. Since 70% of all MDxHealth ConfirmMDx cases are billed to commercial
and third-party payers, these contracts are very important," said Dr. Jan
Groen, CEO of MDxHealth. "With the addition of Stratose to our existing payer
agreements, more than 80 million covered lives now have access to ConfirmMDx
for Prostate Cancer."
Stratose (formerly operating as Coalition America, NPPN, OPPN, PlanCare
America, 4MOST Health, Qualident and KeyClaims) works to reduce the cost and
ensure the best financial results on every medical, dental and workers'
compensation claim for any claims payer. The company maintains one of the
largest directly managed PPO networks in the U.S., including more than 850,000
direct and affiliate medical, dental and workers' compensation provider
MDxHealth is a molecular diagnostics company that develops and commercializes
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients. The company's first commercial product, ConfirmMDx^TM for
Prostate Cancer, has been shown to help distinguish patients who have a
true-negative biopsy from those who may have undetected cancer. MDxHealth
helps to address a large and growing unmet medical need for better cancer
diagnosis and treatment information. The company has a proprietary platform
and a strong epigenetic product pipeline focused on the development of
products for prostate, brain and lung cancers. The company is based in Irvine,
California with a European headquarters in Herstal, Belgium. For more
information visit MDxHealth's website at www.mdxhealth.com.
For more information:
Dr. Jan Groen, CEO Mike Sinclair Matt Clawson
MDxHealth Halsin Partners Allen & Caron, Inc
US: +1 949 812 6979 UK: +44 20 7318 2955 US: +1 949 474 4300
BE: +32 43642070 Cell:+44 7968 022075
email@example.com firstname.lastname@example.org email@example.com
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation. This press release does not
constitute an offer or invitation for the sale or purchase of securities or
assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be
offered or sold within the United States without registration under the U.S.
Securities Act of 1933, as amended, or in compliance with an exemption
therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks
or registered trademarks of MDxHealth SA. All other trademarks and service
marks are the property of their respective owners.
To access the PDF version, please click here
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: MdxHealth (TM) via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.